Message from the Co-Chairs

On behalf of the conference organising committee, it is our pleasure to welcome you, the oncology pharmacists, to the CAPhO’s annual cancer conference – the National Oncology Pharmacy Symposium (NOPS) 2004.

The oncology pharmacists are a diverse group of practitioners – from highly trained individuals who ply their trade in specialised areas to those who contribute occasional but important input into the pharmaceutical care of cancer patients. It is our intention to offer something useful, interesting – and perhaps enlightening – to all of you in this conference. And yes, please take these great opportunities to meet and network with your colleagues across the nation.

NOPS 2004 would not be possible without the enthusiasm and dedication of the organizing committee. As you can see from the membership, we have pharmacists from across the country who volunteered their time for this conference. We sincerely hope that you will have a great experience over this weekend and if so, perhaps join the committee for NOPS 2005 by contacting one of us or the CAPhO executive. Finally, we would like to thank the generous support of our pharmaceutical sponsors and invite you to visit their displays on Saturday.

True knowledge, as they say, cannot be taught, and the best teachers are the student themselves. We salute all of you who have the effort to come to NOPS 2004 for continuing education in oncology pharmacy.

Enjoy the conference!

Yours sincerely,

Mário de Lemos

Victoria Kyritsis
For second-line treatment of CLL... Choose Fludara® Oral First

- Evidence — Proven efficacy and safety profile\(^1,2\)
- Bioavailability — 50-65% and not significantly affected by food\(^1\)
- Convenience — Offers patient the freedom of at-home administration
- Safety Profile — No unexpected or previously unreported signs of toxicity\(^1,2\)*

FLUDARA® Oral (fludarabine phosphate) should be restricted to second-line therapy in patients with CLL who have failed other conventional therapies. Patients should be treated only by physicians skilled in the use of chemotherapeutic agents and regular follow-up of patients is necessary.

FLUDARA® is contraindicated in patients with hypersensitivity to this drug or its components, in patients with neutrophil count <500 cells/mm\(^3\), and in patients with uncorrected bleeding disorders. Use in combination with pentostatin is contraindicated. Use during pregnancy and lactation.

The most common adverse events occurring with FLUDARA® use include myelosuppression (anemia, leukopenia, neutropenia and thrombocytopenia) leading to decreased resistance to infections, including pneumonia, fever and chills. Other commonly reported events include diarrhea, nausea, vomiting, and rash. Severe opportunistic infections have occurred in patients treated with FLUDARA®. Fatality as a result of serious adverse events have been reported.\(^2\)

WARNING: FLUDARA® should be administered under supervision of, or as prescribed by a qualified physician experienced in antineoplastic therapy. FLUDARA® can severely depress bone marrow function. At high doses in dose-ranging studies in patients with acute leukemia, FLUDARA® was associated with severe irreversible neurologic effects, including blindness, coma and death. Instances of life-threatening and sometimes fatal autoimmune hemolytic anemia have been reported during or after treatment. Therapy should be discontinued in the event of hemolyisis. Use in combination with pentostatin is not recommended.

For complete warnings and precautions, please refer to the product monograph. Product monograph and data on file available to healthcare professionals upon request.

*Prospective, multicentre, open label, uncontrolled, phase II study of 78 previously treated CLL patients who had failed to respond to, or showed signs of disease progression, during or after treatment with at least one standard alkylating agent-containing regimen. Dosing was 40 mg/m\(^2\) of FLUDARA oral for 5 consecutive days repeated every 4 weeks for 6 cycles. Efficacy determined by National Cancer Institute (NCI) response criteria.

BERLEX CANADA INC., 2250 32nd Avenue, Lachine, Quebec, H8T 3H4
Visit us at www.berlex.ca

\(^*\) FLUDARA ORAL is a registered trademark of Berlex Canada Inc.

-2-
### CAPhO Executive Committee

<table>
<thead>
<tr>
<th>Name</th>
<th>Organization</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dana Cole</td>
<td>Northern Health Authority</td>
<td>Prince George, BC</td>
</tr>
<tr>
<td>Member-at-Large</td>
<td></td>
<td></td>
</tr>
<tr>
<td>George Dranitsaris</td>
<td>Consultant Pharmacist</td>
<td>Toronto, ON</td>
</tr>
<tr>
<td>Past-President</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gabriel Gazze</td>
<td>MUHC - Royal Victoria Hospital</td>
<td>Montreal, Quebec</td>
</tr>
<tr>
<td>President- Elect</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Betty Riddell</td>
<td>Saskatoon, SK</td>
<td></td>
</tr>
<tr>
<td>Secretary</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lai Schrader</td>
<td>Edmonton, AB</td>
<td></td>
</tr>
<tr>
<td>Member-at-Large</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kim Stefaniuk</td>
<td>Cancer CareOntari</td>
<td>Toronto, ON</td>
</tr>
<tr>
<td>Education Chair</td>
<td>Princess Margaret Hospital</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Susan Walisser</td>
<td>B.C. Cancer Agency</td>
<td></td>
</tr>
<tr>
<td>NCIC Liaison</td>
<td>Vancouver Island Centre</td>
<td>Victoria, BC</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>John Wiernikowski</td>
<td>McMaster Children's Hospital</td>
<td>Ontario</td>
</tr>
<tr>
<td>Treasurer Hamilton</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lynne Nakashima</td>
<td>B.C. Cancer Agency</td>
<td>Vancouver BC</td>
</tr>
<tr>
<td>President</td>
<td>Vancouver Centre</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
*Moments like these are precious.*

With advances in cancer care, she can focus her energy on things that matter most. For more than a century, we have discovered some of the most important medicines that change our daily lives. Our research efforts span many spheres including cancer. Scientists at the Merck Frosst Centre for Therapeutic Research are committed to discovering today for a better tomorrow. As long as there is disease and suffering, we will continue our search.

Please visit our website at: www.merckfrosst.com

MERCK FROSST
Discovering today for a better tomorrow.
## NOPS Organizing Committee Members

<table>
<thead>
<tr>
<th>Name</th>
<th>Organization</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>Venetia Bourrier</td>
<td>CancerCare</td>
<td>Manitoba, MB</td>
</tr>
<tr>
<td>Carol Chambers</td>
<td>Alberta Cancer Board</td>
<td></td>
</tr>
<tr>
<td>Flay Charbonneau</td>
<td>Sunnybrook Regional Cancer Centre</td>
<td>Toronto, ON</td>
</tr>
<tr>
<td>Mário de Lemos</td>
<td>BC Cancer Agency</td>
<td>Vancouver, BC</td>
</tr>
<tr>
<td>Roxanne Dobish</td>
<td>Cross Cancer Institute Pharmacy</td>
<td>Edmonton, AB</td>
</tr>
<tr>
<td>Gabriel Gazzé</td>
<td>MUHC – Royal Victoria Hospital</td>
<td>Montreal, QC</td>
</tr>
<tr>
<td>Victoria Kyritsis</td>
<td>BC Cancer Agency</td>
<td>Vancouver, BC</td>
</tr>
<tr>
<td>Kim Stephanuik</td>
<td>Cancer Care Ontario</td>
<td>Toronto, ON</td>
</tr>
<tr>
<td>Pat Trozzo</td>
<td>CancerCare</td>
<td>Manitoba, MB</td>
</tr>
<tr>
<td>Susan Walisser</td>
<td>NCIC Liaison</td>
<td>Toronto, ON</td>
</tr>
</tbody>
</table>
Lunchtime CAPhO AGM and Awards

12:30 Saturday October 23rd

Introduction to current CAPhO Executive and Committees

Acknowledgment of Pharmacy Industry Partners

National Representation

Current Initiatives

Awards Program

16:30 Saturday October 23rd

Introduction

Financial Report

Standards of Oncology Pharmacy Practice

Oncology Pharmacy as a Specialty Practice

National Education Program

Other Business
PERSPECTIVES IN ONCOLOGY PHARMACY
POP at NOPS Program

Friday, October 22nd

13:00 - 18:00  • Sponsored Pre Conference Workshop:
               Supportive-Care Issues in Cancer:
               An Update for the Oncology Pharmacist (Merck Frosst)
               Forest Hill Ballroom

18:00 – 22:00  • Satellite Symposium: Post ASCO 2004 Update on NSCLC (GlaxoSmithKline)
               High Park Ballroom

Saturday, October 23rd

07:00 - 08:30  • Satellite Symposium: Alemtuzumab (Campath 1H®) Update (Berlex)
               High Park Ballroom

08:00          • Continental Breakfast for POP at NOPS
               Yorkville Room

08:30          • Welcome and Introduction

08:35          • Plenary Session: Where is Oncology Pharmacy Going?
               Presenter: Larry Broadfield, Cancer Care Nova Scotia
               High Park Ballroom

09:05          • Symptom Management: Neuropathic Pain
               Presenter: Carlo DeAngelis, Sunnybrook & Women’s College Health Sciences Centre, Toronto
               High Park Ballroom

09:35          • Does HRT Increase the Risk of Breast Cancer:
               A Critical Review of the Literature Using Meta-Regression Analysis
               Presenter: Linda Lévesque, McGill Pharmacoepidemiology Research Unit
               High Park Ballroom

10:15          • Break
               High Park Ballroom

10:45          • New Drug Update: Bortezomib (Velcade®)
               Presenter: Pam Rudkin, HealthCare Corporation of St. John’s

               • New Drug Update: Bevacizumab (Avastin™) and Cetuximab (Erbitux™)
               Presenter: Pat Trozzo, CancerCare Manitoba
               High Park Ballroom

11:30          • The More Alternatives, the More Difficult the Choice:
               A Review of Adjuvant Systemic Therapy for Breast Cancer
               Presenter: Mark Clemons, Toronto Sunnybrook Regional Cancer Centre
               High Park Ballroom

12:30 – 13:00  • CAPho AGM and Awards
               Forest Hill Ballroom

13:00 – 14:30  • Lunch
               High Park Ballroom
Saturday, October 23rd

14:30 - 15:30 • Breakout #A1 — Overview of Common Drug Review
Presenter: Elaine MacPhail,
Canadian Coordinating Office for Health Technology Assessment
McBride Room

• Breakout #A2 — New Therapies in Clinical Practice: The Results of NCIC Clinical Trials
Presenters: NCIC Pharmacy Network Disease Site Group Representatives
Yorkville Room

• Breakout #A3 — Cancer Pathology: What’s in it for the Pharmacist?
Presenter: Mário de Lemos, British Columbia Cancer Agency
Summerhill Room

15:30 – 16:30 • Breakout # B1 — Mistakes, Misinterpretations and Misadventures: Medication Error
Prevention in Oncology
Presenters: Roxanne Dobish and Cathy Duong, Alberta Cancer Board
Yorkville Room

• Breakout # B2 — A Pharmacist Managed Anticoagulation Clinic: The Clot Thickens
Presenter: Eva Szponarska-Smith, CancerCare Manitoba
Summerhill Room

• Breakout #B3 — Influence Drug Use: Consider Pharmacy-Based Research
Presenter: Carole Chambers, Alberta Cancer Board

16:30 • CAPHO AGM
Forest Hill Ballroom

17:00 – 19:00 • Satellite Symposium: Proteasome Inhibition in Hematological Malignancies
(Ortho Biotech Canada)
High Park Ballroom

Sunday, October 24th 2004

07:00 – 09:00 • Satellite Symposium: Benefit/Risk of Endocrine Adjuvant Therapy (BEAT) - Breast Cancer
(Pfizer Oncology)
High Park Ballroom

08:30 – 09:00 • Continental Breakfast
Yorkville Room

09:00 • GlaxoSmithKline Supportive Care Research Grant for Oncology – Award Winner
Presentation: “A Comparison of Low-Dose with Standard-Dose Filgrastim following
Peripheral Blood Stem Cell Transplant in Lymphoma and Multiple Myeloma Patients”
Presenter: Wayne Cottrell, Princess Margaret Hospital, Toronto
Forest Hill Ballroom

• Theme: A Taste of “POP”: Perspectives on Oncology Pharmacy

09:15 • Overview of Workplace Contamination Issues
Presenter: Dianne Kapty, British Columbia Cancer Agency
Forest Hill Ballroom
10:00
• Break
  Yorkville Room

10:30
• How Do You “Become” an Oncology Pharmacist: Opportunities for Oncology Pharmacy Training and Education
• Board Certification
  Presenter: Lucie Surprenant, St. Mary’s Hospital Center, Montreal

• The Manitoba Experience: Disease Site Modules-Case Based Learning
  Presenter: Shana Robertson, CancerCare Manitoba

• The BC Experience: Pharmacy Communities Oncology Network Educators
  Presenter: Rhonda Kalyn, British Columbia National View

• National View
  Presenter: Kim Stefaniuk, CAPhO Education Chair

• Part-Time Academic Courses: Get Another Degree While You Are Working
  Presenter: Mario de Lemos, British Columbia Cancer Agency
  Forest Hill Ballroom

12:00
• Closing Remarks
  Forest Hill Ballroom
Faculty
Larry Broadfield, B.Sc (Pharm), MHSc, FCSHP
Manager Systemic Therapy Program
Cancer Care Nova Scotia, NS

Mark Jonathan Clemons, BMedSci(Hons), MB BS, MRCP (London), MSc, MD
Clinical Investigator
Toronto Sunnybrook Regional Cancer Centre, ON

Carole Chambers, B.Sc (Pharm) MBA
Director of Pharmacy, Alberta Cancer Board, AB

Flay Charbonneau, B.Sc (Pharm)
Manager, Pharmacy
Toronto Sunnybrook Regional Cancer Centre, ON

Wayne Cottrell, B.Sc (Pharm)
Princess Margaret Hospital

Carlo DeAngelis, Pharm.D
Clinical Pharmacy Co-ordinator - Oncology
Sunnybrook and Women’s College Health Sciences Centre

Roxanne Dobish, B.Sc. (Pharm)
Assistant Director of Pharmacy,
Alberta Cancer Board, AB

Cathy Duong, B.Sc (Pharm)
Community Cancer Network Pharmacy Coordinator,
Alberta Cancer Board, AB

H. Lee Gordon B.Sc (Pharm),
Charge Pharmacist, Lethbridge Cancer Centre, AB

Mário de Lemos M.Sc (Clin Pharm), Pharm.D.
Provincial Drug Information Coordinator, BC Cancer Agency

Linda Levesque, B.Sc (Pharm), MSc., PhD
Candidate McGill Pharmacoepidemiology, Research Unit Division of Clinical Epidemiology, Royal Victoria Hospital, Montreal.

Rhonda Kalyn, BSP
CON (Communities Oncology Network) Pharmacy Educator

Kim Stephanuik, B.Sc (Pharm)
Cancer Care Ontario, ON

Eva Szponarska-Smith, BSc (Pharm)
Department of Pharmacy
CancerCare Manitoba

Elaine McPhail, B.Sc (Pharm)
Common Drug Review

Dianne Kapty, B.Sc (Pharm)
Pharmacy Professional Practice Leader
Fraser Valley Centre – BC Cancer Agency

Shana L. Robertson, B.G.S., B.Ed. (A.D.)
Cancer Care Manitoba Education Coordinator,
Community Cancer Programs Network
Cancer Care Manitoba

Pamela Rudkin, PhC
HealthCare Corporation of St. John’s

Biljana Spirovski
Pharmacist,
Humber River Regional Hospital, Toronto, ON

Marlene Sellon, B.Sc (Pharm)
Pharmacist for QE11 Health Science Centre
Cancer Care, Nova Scotia, NS

Lucie Surprenant, B. Pharm., M.Sc. (Hôp.), BCOP
St Mary’s Hospital Center, Montreal, PQ

Pat Trozzo B.Sc. (Chem), B.Sc (Pharm)
BCPS Oncology Pharmacist/ Site Manager
Cancer Care Manitoba
Assistant Professor
Faculty of Pharmacy University of Manitoba

Susan Wallisser
NCIC Liaison
### Speaker Biographies

<table>
<thead>
<tr>
<th>Name</th>
<th>Title and Institution</th>
</tr>
</thead>
</table>
| **Larry Broadfield, B.Sc Pharm, MHSc, FCSHP** | Manager Systemic Therapy Program  
Cancer Care Nova Scotia                                     |
| **Mark Jonathan Clemons, BMedSci(Hons), MB BS, MRCP (London), MSc, MD** | Clinical Investigator, Toronto Sunnybrook Regional Cancer Centre |
| **Carole Chambers, B.Sc (Pharm) MBA**      | Alberta Cancer Board, Director of Pharmacy                 |
| **Flay Charbonneau, B.Sc (Pharm)**        | Manager, Pharmacy                                           |
|                                            | Toronto Sunnybrook Regional Cancer Centre                  |
| **Wayne Cottrell B.Sc (Pharm), Princess Margaret Hospital** |                                             |
| **Carlo DeAngelis, Pharm.D.**              | Clinical Pharmacy Coordinator - Oncology                  |
|                                            | Sunnybrook and Women’s College Health Sciences Centre      |

Mark Clemons is married with two young children and in his spare time is a staff Medical Oncologist and Clinician Investigator at the Toronto Sunnybrook Regional Cancer Centre. He is also an Assistant Professor in Medicine at the University of Toronto. He has published widely on breast cancer risk factors in general and on clinical trials of breast cancer treatments. He is also a great fan of NOPS as he feels true collaboration between different disciplines will ultimately lead to better treatment for our patients.

Carole Chambers has practiced in oncology pharmacy for over 20 years. She holds adjunct appointments at two universities, and has published 24 papers in peer reviewed journals with the focus on practice based research.

Flay Charbonneau is the Manager, Pharmacy at the Toronto Sunnybrook Regional Cancer Centre and has been with the Oncology program at Sunnybrook & Women’s for the past 15 years. Her responsibilities include administrative, clinical and drug distribution activities. Flay’s clinical interests include breast cancer, colorectal cancer and prostate cancer.

She is also involved with administrative projects such as accreditation, implementation of CPOE (computerized physician order entry) within the hospital and quality improvement initiatives, such as reducing wait times for chemotherapy.

Flay is a member of the NCIC CTG Breast Site group and is a member of the planning committee for NOPS. Flay and her husband Steve have two teenagers, Trevor and Shannon. They enjoy skiing, biking, golf, boxing and generally keeping fit.

Carlo obtained his Bachelor of Science in Pharmacy (1981) from the University of Toronto and his Doctor of Pharmacy (1984) from the State University of New York at Buffalo.

Carlo’s area of specialization in Oncology Clinical Pharmacy Practice is symptom management, specifically pain management and end of life symptom control. As well as prevention and management of antineoplastic systemic therapy related side effects.

He has a particular interest in professional adult life long learning and training. An extension of this interest includes patient education and counseling.
**Roxanne Dobish, B.Sc. (Pharm), Assistant Director of Pharmacy, Alberta Cancer Board**

Roxanne has worked in Oncology Pharmacy for over 16 years in a variety of roles that include staff pharmacist, involvement in the community cancer program implementation, and various management positions. Areas of interest and specialization include medication error prevention, community cancer network, chemotherapy handling and certification, policy and procedure development. Involved with projects related to medication error prevention such as provincial policy development and implementation, development of medication error prevention tools for staff and staff training, multidisciplinary presentations, and lectures to pharmacy students.

**Cathy Duong, B.Sc (Pharm)**

**Community Cancer Network Pharmacy Co-ordinator, Alberta Cancer Board**

Cathy Duong graduated from the University of Alberta and completed a hospital residency. She worked in various retail settings and in the hospital on the Coronary, Surgical and Bone Marrow Transplant Units. She is currently the Community Cancer Care Network Coordinator and a member of the Medication Prevention Committee for the Alberta Cancer Board Pharmacy. She developed the Oncology Medication Error Prevention CE Module for the staff members. Cathy has a keen interest in adult education. She has been a preceptor and lecturer for Pharmacy students for many years. She has also presented and chaired numerous Pharmacy Continuing Education workshops.

**H. Lee Gordon, B.Sc. (Pharm), Charge Pharmacist, Lethbridge Cancer Centre**

B.Sc. (Pharm) U of Alberta; Pharm. D. Candidate University of Montana

**Mário de Lemos, MSc (Clin Pharm), Pharm.D.**

**Provincial Drug Information Coordinator, BC Cancer Agency**

Mário de Lemos obtained his B.Sc.(Hons)(Pharm) (1987) and M.Sc. (Clin. Pharm) (1997) from Britain and his Pharm.D. from the University of British Columbia (1999). He has experience in-community and hospital practice, and is currently the Provincial Drug Information Coordinator of the British Columbia Cancer Agency. Mário’s current research interests include renal safety of pamidronate and the accuracy of creatinine-based formulas for cancer drug dosing. He is the principal recipient of the C.S.H.P. 2003 research grant, 2000 award for oncology and 2003 award for patient care enhancement. Mário has been studying part-time for his M.Sc. (Oncology) since 2002.

**Linda Levesque, B.Sc (Pharm), MSc, PhD**

**Candidate McGill Pharmacoepidemiology, Research Unit Division of Clinical Epidemiology, Royal Victoria Hospital, Montreal.**

Linda received her pharmacy degree from the University of Toronto. She has worked in a variety of practice settings, including community, long-term care, and hospital. She spent 15 years working in teaching hospitals, the last 10 as a Coordinator of Clinical Pharmacy Services. She has received numerous CSHP and academic awards, including a research training fellowship from the McGill University Health Centre (MUHC) Research Institute. Linda currently holds a Doctoral Fellowship in Pharmacoepidemiology from Merck Foundation. In 1997, Linda enrolled in the Epidemiology and Community Health program at Queens University where she obtained a Master of Science. Linda is in her final year of doctoral studies in Epidemiology and Biostatistics at McGill University, where she is specializing in Pharmacoepidemiology.
Rhonda Kaly, BSP  
**CON (Communities Oncology Network) Pharmacy Educator**  
After seven years of retail pharmacy in Saskatchewan, Rhonda moved to Sechelt, B.C. About a year later she made the switch to hospital pharmacy and went to work for Kelowna General Hospital. In 2001, Rhonda went to work for the BC Cancer Agency in Kelowna. Her field of specialization is Oncology.

Kim Stephanuik, Cancer Care Ontario  
A proud Western Canadian, Kim obtained her Bachelor's degree in Pharmacy at the University of Saskatchewan more years ago than she cares to admit. After completing a hospital pharmacy residency at the South Saskatchewan Hospital Centre in Regina, she moved to Ontario where she worked in a community hospital covering services from oncology to pediatrics and psychiatry. She is currently Oncology Pharmacy Education Coordinator for Cancer Care Ontario, a palliative care pharmacist at Princess Margaret Hospital, and occasional oncology pharmacist at Toronto Sunnybrook Regional Cancer Centre. Education Chair and former Treasurer for the Canadian Association of Pharmacy in Oncology, Education Committee and Publications Committee member for International Society of Oncology Pharmacy Practitioners, and active member in other professional organizations, Kim keeps busy organizing conferences, speaking, shaping impressionable young minds, and practice-based research. In her spare time, Kim enjoys gardening, ice dancing, and playing her harp. Oh-and reminding Jeff Barnett that the Toronto Maple Leafs will indeed win the Stanley Cup…this year.

Eva Szponarska-Smith, B. Sc (Pharm)  
Department of Pharmacy  
CancerCare Manitoba, MB  
Eva Szponarska-Smith earned her bachelor degrees in microbiology and in pharmacy at the University of Manitoba. She initially worked as a pharmacist in the Drug Information Department and in the Hemodialysis programme at the Health Sciences Centre in Winnipeg. She joined the Pharmacy department at CancerCare Manitoba in March 2002 and has been working predominantly with the Hematology Disease Site group. Her primary role has been the provision of Anticoagulation Management Services to CancerCare Manitoba patients. She is also slowly making her way up the steep learning curve of pediatric oncology pharmacy.

Elaine McPhail, B.Sc (Pharm)  
Elaine MacPhail is the Director of the Common Drug Review. She is responsible for overseeing the preparation of drug reviews for use by the Canadian Expert Drug Advisory Committee (CEDAC) and for providing support to CEDAC and the Common Drug Review Committee. Elaine first joined the CDR in March 2002 as Coordinator of the Interim CDR process.  
Elaine has many years of experience in a variety of fields of pharmacy practice. Prior to joining CDR, she was a Pharmacist at the Canadian Institute for Health Information (CIHI). Previous to that position, she was Pharmacist Consultant with the First Nations and Inuit Health Branch of Health Canada for six years. There she was responsible for updating and maintaining the Non-Insured Health Benefits Program Drug Benefit List and for providing support to the Federal Pharmacy and Therapeutics Committee. Elaine served as the first Managing Editor of Therapeutic Choices, published by the Canadian Pharmacists Association. Over a period of 14 years Elaine served in various capacities with the Saskatchewan Prescription Drug Plan, including Director of Formulary and Education and Chair of the Saskatchewan Formulary Committee. Throughout the years, she has also practised pharmacy in hospital and community settings and a continuing care facility.  
Elaine holds a BSc. in Pharmacy and Master of Science in Hospital Pharmacy from the University of Alberta.
Dianne Kapty, B.Sc (Pharm)

Fraser Valley Centre – BC Cancer Agency
Dianne Kapty graduated from the University of BC and completed a hospital pharmacy residency at Vancouver General Hospital. She has been an oncology pharmacist since 1982. She developed the BC Cancer Agency pharmacy chemotherapy preparation service, previously done by nurses on the ward. Dianne is Pharmacy Professional Practice Leader for the Fraser Valley Centre in Surrey. As a member of the BCCA Provincial Pharmacy Professional Practice Council, she is responsible for the safe handling of cytotoxic drugs. When not immersed in oncology pharmacy, Dianne likes to run the west dyke trail in Richmond, and to participate in the occasional half marathon.

Shana L. Robertson, B.G.S., B.Ed. (A.D.)

Cancer Care Manitoba Education Coordinator,
Community Cancer Programs Network, Cancer Care Manitoba
Shana Robertson is the Education Coordinator for Cancer Care Manitoba’s Community Cancer Programs Network (CCPN). Shana is a certified teacher who has experience at the university, college and middle/senior year’s public school levels. A life learner, she has taken Masters level courses in educational administration and Masters level courses in coaching while an assistant coach with a university men’s basketball program. She continues to pursue a Masters degree in education. Shana has presented at a local and national level at educational workshops and athletic conferences.

Pamela Rudkin, PhC

HealthCare Corporation of St. John’s
Currently responsible for the Pharmacotherapeutic services for the Hematology-Oncology Division at Health Care Corporation, St. John’s, Newfoundland, Pam is also a Clinical Associate and Guest Lecturer at Memorial University of Newfoundland’s School of Pharmacy.
Pam is a standing member of the Peripheral Stem Cell Transplant, Anticoagulation, and Antibiotic Utilization Committees, and was instrumental in the development of Guidelines for the Hematology Division for the Health Care Corporation. She is also responsible for writing and coordinating chemotherapy protocols for hematology patients. Other teaching responsibilities include the Provincial Oncology Nursing Course. Pam also is responsible for supplying the documentation and obtaining provincial funding for hematology patients throughout the province of Newfoundland and Labrador for medications such as Thalidomide, Eprex, and Gleevec.

Biljana Spirovski, Pharmacist, Humber River Regional Hospital, Toronto.

Biljana is a pharmacist in Oncology and Clinical Trials at Humber River Regional Hospital in Toronto. She has been in this position for 13 years, since its inception. Biljana’s interest and active involvement in Clinical Trials has resulted in her becoming one of the initiators of the Pharmacists’ Network (PN) at the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) in the early nineties. She has served as a member on the symptom Control and Hematology Disease Site Committees and is presently a member of the PN Steering Group.

Marlene Sellon, B.Sc (Pharm),

Pharmacist for QE11 Health Science Centre,
Cancer Care, Nova Scotia
Lucie Surprenant,  B. Pharm., M.Sc. (Hôp.), BCOP
St Mary’s Hospital Center

Lucie Surprenant graduated from Université de Montréal in 1978 and completed a post graduate Diploma in Hospital Pharmacy Practice in 1979, which was transformed to a Masters degree in 1994. She has been working at St. Mary’s Hospital Center in Montreal since 1992 and is responsible for the Oncology Pharmacy Services. She has been a Board Certified Oncology Pharmacist since 2000.

Pat Trozzo, B.Sc (Chem), B.Sc. (Pharm)
BCPS Oncology Pharmacist/ Site Manager, Cancercare Manitoba
Assistant Professor, Faculty of Pharmacy University of Manitoba

After gaining a Bachelor’s degree in Pharmacy (1991) and Bachelor’s degree in Chemistry University of Manitoba (1988), Pat started his career as a staff pharmacist and then a Clinical Pharmacist at the Saint Boniface General Hospital in Winnipeg. In 1993 he began working with CancerCare Manitoba as an Oncology Pharmacist at their St. Boniface unit, where he remains. In 1997 he obtained his designation as a Board Certified Pharmacotherapy Specialist from the American Society of Healthcare Pharmacists. He holds the position of Assistant Professor – Faculty of Pharmacy, University of Manitoba and is involved in the teaching of oncology and pain and symptom management in the undergraduate program.

His area of interest and work is in the treatment of gastrointestinal cancers and he is an active member of the Pain & Symptom control clinic at CancerCare Manitoba.

Susan Wallisser
NCIC Liaison
At Amgen, innovation is in our blood.

Literally.

We nurture a culture that encourages original thinking and a passion for the process of discovery. Our scientists continue to seek out novel human therapeutics, to help improve and simplify the treatment of chemotherapy-induced side effects.

Amgen is dedicated to expanding supportive care for cancer patients receiving chemotherapy.
Synopsis

Larry Broadfield  B.Sc (Pharm), MHSc, FCSHP  
Manager Systemic Therapy Program  
Cancer Care Nova Scotia, NS

The Future of Oncology Pharmacy  
(or A Tale of the Flintstones Meet the Jetsons)

Oncology has made great strides into the future over recent years, but has oncology pharmacy practice kept up? Or are we still living in our own ‘Stone Age’? In this presentation, we will compare our beginnings with our present and gaze into the future.

Have we truly made improvements in the cornerstone of cancer chemotherapy drug preparation practices? Are we ready for the new paradigms of systemic therapy as they are emerging into our practices? Are we ready for the mounting numbers of cancer patients in our tertiary hospitals and our community hospitals? Can we get clinical pharmacists out of the dispensary and up to the wards and ambulatory clinics where the patients are? Can we get the key functions of order verification and dose preparation to be safe and efficient, and how can we incorporate the pharmaceutical care model into our product-driven practices? These questions and more will be addressed.

If our beginnings were like the Flintstones, can we be true to our principles of practice as we are swept into the future, like the Jetsons? This will be a thought-provoking call-to-arms for oncology pharmacists.
**Synopsis**

Carlo DeAngelis, Pharm.D.
Clinical Pharmacy Coordinator - Oncology
Sunnybrook and Women’s College Health Sciences Centre

*Symptom Management: Neuropathic Pain*

**Synopsis**

Linda Levesque, B.Sc (Pharm), MSc., PhD
Candidate McGill Pharmacoepidemiology,
Research Unit Division of Clinical Epidemiology, Royal Victoria Hospital, Montreal.

*Does HRT Increase the Risk of Breast Cancer: A Critical Review of the Literature Using Meta-Regression Analysis*

**Synopsis**

Pamela Rudkin, PhC
HealthCare Corporation of St. John’s

*New Drug Update: Bortezomib (Velcade)*

To review the mechanism of action of Bortezomib in MM, the pivotal clinical trials using Bortezomib in MM, the most frequently observed toxicities of Bortezomib in the clinical trials, and its place in therapy

  • Provide pharmacists with an understanding of the mechanism of action of Bortezomib in Multiple myeloma.
  
  • Review the Phase II Summit trial for Bortezomib in the treatment of multiple myeloma.
  
  • Review the dose schedule, and administration guidelines for Bortezomib.
  
  • Review adverse effects and monitoring parameters associated with the use of Bortezomib.
Synopsis

Pat Trozzo, B.Sc. (Chem), B.Sc (Pharm)
BCPS Oncology Pharmacist/ Site Manager, Cancercare Manitoba
Assistant Professor, Faculty of Pharmacy University of Manitoba

New Drug Update: Bevacizumab (Avastin®) and Cetuximab (Erbitux®)

• Review of possible molecular targets such as vascular endothelial growth factors and epidermal growth factors
• Review of the pharmacokinetic, pharmacodynamic and adverse effect profiles of bevacizumab and cetuximab
• Review of the pivotal clinical trials with these two antibodies in the treatment of colorectal cancer
**Synopsis**

Mark Jonathan Clemons, BMedSci(Hons), MB BS, MRCP (London), MSc, MD  
Clinical Investigator, Toronto Sunnybrook Regional Cancer Centre

“The more alternatives, the more difficult the choice”.  
_A Review of Adjuvant Therapy for Breast Cancer in 2004._

By the end of the session the delegate should have a greater:

- Understanding of the rationale of adjuvant therapy for breast cancer
- Availability of effective tools for estimating the benefits of adjuvant therapy
- Rationale for the use of endocrine and chemotherapy
- Appreciate the complex interaction between the toxicity of modern therapy and potential benefits
- Appreciate that not all medical oncology talks have to be staid and boring!
Synopsis

Elaine MacPhail, Director, Common Drug Review
Canadian Coordinating Office for Health Technology Assessment (CCOHTA)

Overview of Common Drug Review

The Canadian Coordinating Office for Health Technology Assessment (CCOHTA) is an independent not-for-profit organization funded by Canada’s federal, provincial and territorial governments. It supports health care management through three programs: Health Technology Assessment (HTA), the Common Drug Review (CDR) and the Canadian Optimal Medication Prescribing and Utilization Service (COMPUS).

The Common Drug Review (CDR) is a single process for reviewing new drugs and providing a listing recommendation to the federal, provincial and territorial drug benefit plans in Canada (except Quebec). The program was launched in September 2003.

The Common Drug Review Overview presentation will cover:

• what the CDR is
• the evolution of the program
• where CDR fits in the Canadian drug approval and formulary listing processes
• the program objectives
• who is involved in the CDR
• development of the CDR process
• steps in the CDR review and recommendation processes
• transparency
• status report on submissions
• comments on submissions received
• challenges for CDR and CEDAC
• evaluation of the CDR
Synopsis

Marlene Sellon, B.Sc (Pharm),
Pharmacist for QE11 Health Science Centre,
Cancer Care, Nova Scotia

Flay Charbonneau, B.Sc (Pharm),
Manager, Pharmacy, Toronto Sunnybrook Regional Cancer Centre

Biljana Spirovski, Pharmacist,
Humber River Regional Hospital, Toronto.

Susan Walisser, NCIC Liaison

Lee Gordon, B.Sc. (Pharm),
Charge Pharmacist, Lethbridge Cancer Centre

New Therapies in Clinical Practice: The results of NCIC Clinical Trials

The National Cancer Institute of Canada (NCIC) Clinical Trials Group (CTG) has recently reported on a number of pivotal clinical trials at the NCIC Spring Meeting in April 2004 and at the American Society of Clinical Oncology (ASCO) meeting in June 2004. This presentation will highlight five (5) important Canadian Clinical Trials which will significantly impact the standard of practice in Oncology. The disease sites to be discussed include; CNS (CE.3), Hematology (LY.9), Breast (MA.17) and Lung (BR.10 and BR.21). A member of the NCIC Pharmacists Network Steering Group or a Disease Site Representative will present each trial.

Educational Objectives
• To increase the awareness of the NCIC CTG clinical trials and the NCIC Pharmacists Network
• To review the clinical data as reported in each disease site
• To review the clinical and statistical outcomes of each trial
• To describe the anticipated shift in the standard of practice in oncology
• To promote the contribution that Canadian Pharmacists are making to the evolution of the standard of care for cancer patients.

__________________________________________________________

__________________________________________________________

__________________________________________________________

__________________________________________________________

__________________________________________________________

__________________________________________________________
Synopsis

Mário de Lemos, M.Sc (Clin Pharm), Pharm.D.
Provincial Drug Information Coordinator, BC Cancer Agency

Cancer Pathology: What's in it for the Pharmacist?

Pathology plays a more prominent role in the treatment of cancer than of many other diseases. Unlike say, congestive heart failure or diabetes – often defined to a large extent by the clinical manifestations – cancer is classified and diagnosed at the tissue level. Cancer is not a single disease but a family of diseases, and the associated clinical features are often non-specific. Hence, cancer is usually described in terms of histopathology rather than pathophysiology. An accurate pathological description of a cancer case is essential to help decide the choice of drug regimens as well as to predict and monitor the efficacy of the treatment. Although basic pathology courses may be offered at the undergraduate or postgraduate pharmacy level, cancer pathology is often not fully discussed at these courses or during undergraduate medical training.

During this presentation, I would like to share with you some of the things that I learned from a recent cancer pathology course, as part of the M.Sc. in Oncology program, University of Newcastle, United Kingdom. I am grateful that Brian Angus, Ph.D., F.R.C.Path., for allowing me to use the materials he developed for this course.

Objectives
The audience should be able to do the following at the end of the presentation:
• Give three uses of pathology in cancer drug therapy.
• Describe the major features of a malignant cell.
• Describe the common clinical manifestations of a malignant disease.
Synopsis

**Roxanne Dobish**, B.Sc. (Pharm),
Assistant Director of Pharmacy, Alberta Cancer Board

**Cathy Duong**, B.Sc(Pharm),
Community Cancer Network Pharmacy Co-ordinator, Alberta Cancer Board

*Mistakes, Misinterpretations and Misadventures: Medication Error Prevention in Oncology*

Workshop participants will:

- Gain awareness of common medication errors in oncology
- Practice detecting oncology related medication errors
- Share in discussion of medication error prevention initiatives

Synopsis

**Eva Szponarska-Smith**, B.Sc.(Pharm)

*A Pharmacist Managed Anticoagulation Clinic: The Clot Thickens*
Synopsis

Carole Chambers, B.Sc (Pharm) MBA
Alberta Cancer Board, Director of Pharmacy

Influence Drug Use: Consider Research

Learning Objectives:
• Examine the changing/enlarging aspects of clinical trials to meet the needs of the decision making audience
• Identify potential pharmacy Research opportunities that build on DUR strengths
• Share lessons learned on published effectiveness projects
• Generate ideas/ new projects for Oncology Pharmacist to pursue post NOPS 2004

Synopsis

Wayne Cottrell, B.Sc(Pharm), Princess Margaret Hospital

A Comparison of Low-Dose with Standard-Dose Filgrastim Following Periphal Blood Stem Cell Transplant in Lymphoma and Mulitple Myeloma Patients
Synopsis

Dianne Kapty, B.Sc (Pharm)
Pharmacy Professional Practice Leader
Fraser Valley Centre, – BC Cancer Agency

Overview of Workplace Contamination

• Recognition of recent evidence of surface contamination with cytotoxic drugs despite preparation in a biological safety cabinet using recognized procedures and equipment.

• Use of the NIOSH Alert “Preventing occupational exposures to the antineoplastic and other hazardous drugs in health care settings” to fine-tune the safe handling of cytotoxic drugs.

• Awareness of the USP Chapter 9797 “Pharmaceutical compounding – sterile preparations”, which will also influence the preparation of cytotoxic drugs.

Synopsis

Lucie Surprenant, BPharm., MSc. (Hôp.), BCOP, St Mary’s Hospital Center

Board Certification

After this presentation, the participant will be able to:

• Describe the Board Certification Process

• Obtain more information on the ACCP Website

• Appreciate the pros and cons of this program
Synopsis

Shana L. Robertson, B.G.S., B.Ed. (A.D.)
Cancer Care Manitoba Education Coordinator,
Community Cancer Programs Network, Cancer Care Manitoba

The Manitoba Experience: Disease Site Modules-case Based Learning

This presentation will outline the format, process and experience CCMB’s Department of Pharmacy and Community Cancer Programs Network (CCPN) had while jointly developing this specialized oncology training. This needs based curriculum was created following a comprehensive survey of Manitoba’s pharmacists who provide clinical support for Manitoba’s 14 Community Cancer Program “outreach” sites. The modules in the curriculum are centered around individual Disease Site Groups (DSG) and contain information on the common types of cancers within each DSG. Each module contains information on the types of cancer most commonly encountered within the DSG, symptoms, diagnosis, staging, treatment options (with current regiments used in Manitoba), recurrence/salvage therapy and a list of references associated with the preparation of the module. Modules will be updated regularly to ensure they are current and relevant. Each module was authored by a CCMB pharmacist who has been assigned to the specific DSG and reviewed by the Chair of each DSG.
Synopsis

Rhonda Kalyn, BSP, CON (Communities Oncology Network) Pharmacy Educator

The BC Experience: Pharmacy Communities Oncology Network Educators

• To describe the structure of the BC Cancer Agency and its relationship to its neighboring communities.
• To explain the history of the development of the CON Pharmacy Educators.
• To describe the 2002 Pharmacy needs assessment and how it influences the development of continuing education programs by the CON Pharmacy Educators.
• To describe the activities and projects of the CON pharmacy Educators.
Synopsis

Kim Stephanuk, Cancer Care Ontario, ON

National View

---

Synopsis

Mário de Lemos, M.Sc (Clin Pharm), Pharm.D.
Provincial Drug Information CoordinatorBC Cancer Agency

Part-time Academic Courses: Get Another Degree While You Are Working

Postgraduate pharmacy training in the United Kingdom has followed a different path from that undertaken in Canada. Most pharmacists upgrade their practice through formal courses offered by universities, most of which are studied through part-time or distance learning. Hence, it is possible that pharmacists in Canada can pursue some of these courses (e.g., M.Sc. in Clinical Pharmacy from the Queen’s University of Belfast, M.Sc. in Epidemiology from the London School of Hygiene and Tropical Medicine).

During this presentation, I would like to share my experience as a student of the distance-learning program in oncology and palliative care offered by the University of Newcastle. This program is mainly aimed at physicians training for clinical oncology but also opened to qualified pharmacists, nurses, and other health professionals. Students can pursue just the core modules for a certificate in cancer studies or further specialize for a diploma in oncology or palliative care. The M.Sc. in oncology or palliative care would be awarded after an additional research project.

Objective

The audience should be able to describe the major features of distance-learning postgraduate courses available in the United Kingdom.
OUR COMMITMENT CONTINUES
AN ACTIVE AND CARING SPONSOR OF NOPS 2004

Bristol-Myers Squibb Canada
ONCOLOGY

Now more than ever, we're with you

...Because Health Matters

Sanofi-Synthelabo is a major global pharmaceutical company with more than 30,000 employees in more than 100 countries. Sanofi-Synthelabo is a dynamic, rapidly growing organization that is working to meet the healthcare needs of physicians and their patients.

The company focuses on four core therapeutic areas: cardiovascular disease and thrombosis, diseases of the central nervous system, oncology and infection medicine. And, we are committed to researching, developing and bringing to market new compounds so we can fulfill our mission.

...Because Health Matters

It's all about building a company with one and only one mission: to fight for what really matters – health.

Sanofi-Synthelabo